Search

Your search keyword '"Ara, Takahide"' showing total 158 results
Start Over Author "Ara, Takahide" Language english
158 results on '"Ara, Takahide"'

1. HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA heterozygous donors: a retrospective nationwide analysis

Author

Fukunaga, Keiko, Ikegame, Kazuhiro, Nakamae, Hirohisa, Doki, Noriko, Fukuda, Takahiro, Kondo, Yukio, Ara, Takahide, Eto, Tetsuya, Mori, Yasuo, Matsuoka, Ken-ichi, Kanda, Yoshinobu, Onizuka, Makoto, Atsuta, Yoshiko, Ichinohe, Tatsuo, Morishima, Satoko, and Kanda, Junya

Published
2024
Full Text
View/download PDF

2. Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection

Author

Takenaka, Katsuto, Fuji, Shigeo, Matsukawa, Toshihiro, Uchida, Naoyuki, Kobayashi, Takeshi, Tanaka, Masatsugu, Ara, Takahide, Ikegame, Kazuhiro, Ozawa, Yukiyasu, Kanda, Yoshinobu, Sawa, Masashi, Maruyama, Yumiko, Fukuda, Takahiro, Nakamae, Hirohisa, Kimura, Takafumi, Ogata, Masao, Seo, Sachiko, Atsuta, Yoshiko, Matsuo, Keitaro, and Nakasone, Hideki

Published
2024
Full Text
View/download PDF

5. Impact of HLA disparity on overall mortality risk in patients with extensive chronic GVHD: The HLA Working Group of Japanese Society for Transplantation and Cellular Therapy

Author

Fuji, Shigeo, Hakoda, Akitoshi, Kanda, Junya, Fukuda, Takahiro, Doki, Noriko, Katayama, Yuta, Uchida, Naoyuki, Ozawa, Yukiyasu, Kanda, Yoshinobu, Tanaka, Masatsugu, Kataoka, Keisuke, Ara, Takahide, Sawa, Masashi, Onizuka, Makoto, Onishi, Yasushi, Kimura, Takafumi, Ichinohe, Tatsuo, Atsuta, Yoshiko, Shintani, Ayumi, and Morishima, Satoko

Published
2023
Full Text
View/download PDF

6. External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia

Author

Yanada, Masamitsu, Shimomura, Yoshimitsu, Mizuno, Shohei, Matsuda, Kensuke, Kondo, Tadakazu, Doki, Noriko, Tanaka, Masatsugu, Fukuda, Takahiro, Ara, Takahide, Uchida, Naoyuki, Onizuka, Makoto, Sawa, Masashi, Ozawa, Yukiyasu, Hiramoto, Nobuhiro, Ota, Shuichi, Kanda, Junya, Kanda, Yoshinobu, Ichinohe, Tatsuo, Okamoto, Shinichiro, Atsuta, Yoshiko, and Konuma, Takaaki

Published
2023
Full Text
View/download PDF

7. Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group

Author

Saburi, Masuho, Oshima, Kumi, Takano, Kuniko, Inoue, Yoshitaka, Harada, Kaito, Uchida, Naoyuki, Fukuda, Takahiro, Doki, Noriko, Ikegame, Kazuhiro, Matsuo, Yayoi, Katayama, Yuta, Ozawa, Yukiyasu, Matsuoka, Ken-ichi, Kawakita, Toshiro, Mori, Yasuo, Ara, Takahide, Nakamae, Hirohisa, Kimura, Takafumi, Kanda, Yoshinobu, Atsuta, Yoshiko, and Ogata, Masao

Published
2023
Full Text
View/download PDF

10. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database

Author

Itonaga, Hidehiro, Miyazaki, Yasushi, Aoki, Kazunari, Shingai, Naoki, Ozawa, Yukiyasu, Fukuda, Takahiro, Kataoka, Keisuke, Kawakita, Toshiro, Ueda, Yasunori, Ara, Takahide, Tanaka, Masatsugu, Katayama, Yuta, Sawa, Masashi, Eto, Tetsuya, Kanda, Junya, Atsuta, Yoshiko, and Ishiyama, Ken

Published
2023
Full Text
View/download PDF

11. Author Correction: A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Author

Jo, Tomoyasu, Arai, Yasuyuki, Kanda, Junya, Kondo, Tadakazu, Ikegame, Kazuhiro, Uchida, Naoyuki, Doki, Noriko, Fukuda, Takahiro, Ozawa, Yukiyasu, Tanaka, Masatsugu, Ara, Takahide, Kuriyama, Takuro, Katayama, Yuta, Kawakita, Toshiro, Kanda, Yoshinobu, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Terakura, Seitaro

Published
2023
Full Text
View/download PDF

12. A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Author

Jo, Tomoyasu, Arai, Yasuyuki, Kanda, Junya, Kondo, Tadakazu, Ikegame, Kazuhiro, Uchida, Naoyuki, Doki, Noriko, Fukuda, Takahiro, Ozawa, Yukiyasu, Tanaka, Masatsugu, Ara, Takahide, Kuriyama, Takuro, Katayama, Yuta, Kawakita, Toshiro, Kanda, Yoshinobu, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Terakura, Seitaro

Published
2023
Full Text
View/download PDF

14. Effect of the COVID-19 pandemic on allogeneic stem cell transplantation in Japan

Author

Shimomura, Yoshimitsu, Kitamura, Tetsuhisa, Nishikubo, Masashi, Sobue, Tomotaka, Uchida, Naoyuki, Doki, Noriko, Tanaka, Masatsugu, Ito, Ayumu, Ishikawa, Jun, Ara, Takahide, Ota, Shuichi, Onizuka, Makoto, Sawa, Masashi, Ozawa, Yukiyasu, Maruyama, Yumiko, Ikegame, Kazuhiro, Kanda, Yoshinobu, Ichinohe, Tatsuo, Fukuda, Takahiro, Okamoto, Shinichiro, Teshima, Takanori, and Atsuta, Yoshiko

Published
2023
Full Text
View/download PDF

15. Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation

Author

Kamijo, Kimimori, Shimomura, Yoshimitsu, Shinohara, Akihito, Mizuno, Shohei, Kanaya, Minoru, Usui, Yoshiaki, Kim, Sung-Won, Ara, Takahide, Mizuno, Ishikazu, Kuriyama, Takuro, Nakazawa, Hideyuki, Matsuoka, Ken-ichi, Kusumoto, Shigeru, Maseki, Nobuo, Yamaguchi, Masaki, Ashida, Takashi, Onizuka, Makoto, Fukuda, Takahiro, Atsuta, Yoshiko, and Kondo, Eisei

Published
2023
Full Text
View/download PDF

17. Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT

Author

Senjo, Hajime, Harada, Shinpei, Kubota, Shimpei I., Tanaka, Yuki, Tateno, Takahiro, Zhang, Zixuan, Okada, Satomi, Chen, Xuanzhong, Kikuchi, Ryo, Miyashita, Naoki, Onozawa, Masahiro, Goto, Hideki, Endo, Tomoyuki, Hasegawa, Yuta, Ohigashi, Hiroyuki, Ara, Takahide, Hasegawa, Yoshinori, Murakami, Masaaki, Teshima, Takanori, and Hashimoto, Daigo

Published
2023
Full Text
View/download PDF

18. CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia

Author

Akahoshi, Yu, Nakasone, Hideki, Takenaka, Katsuto, Yamasaki, Satoshi, Nakamura, Momoko, Doki, Noriko, Tanaka, Masatsugu, Ozawa, Yukiyasu, Uchida, Naoyuki, Ara, Takahide, Nakamae, Hirohisa, Ota, Shuichi, Onizuka, Makoto, Yano, Shingo, Tanaka, Junji, Fukuda, Takahiro, Kanda, Yoshinobu, Atsuta, Yoshiko, Kako, Shinichi, Yanada, Masamitsu, and Arai, Yasuyuki

Published
2023
Full Text
View/download PDF

21. Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades

Author

Nishiwaki, Satoshi, Akahoshi, Yu, Morita-Fujita, Mari, Shimizu, Hiroaki, Uchida, Naoyuki, Ozawa, Yukiyasu, Fukuda, Takahiro, Tanaka, Masatsugu, Ikegame, Kazuhiro, Ota, Shuichi, Katayama, Yuta, Takahashi, Satoshi, Kawakita, Toshiro, Ara, Takahide, Onizuka, Makoto, Kimura, Takafumi, Tanaka, Junji, Atsuta, Yoshiko, and Arai, Yasuyuki

Published
2022
Full Text
View/download PDF

23. Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors

Author

Tamaki, Masaharu, Kameda, Kazuaki, Kimura, Shun-ichi, Harada, Naonori, Uchida, Naoyuki, Doki, Noriko, Tanaka, Masatsugu, Ikegame, Kazuhiro, Sawa, Masashi, Katayama, Yuta, Miyakoshi, Shigesaburo, Ara, Takahide, Kanda, Junya, Onizuka, Makoto, Fukuda, Takahiro, Atsuta, Yoshiko, Kanda, Yoshinobu, Yakushijin, Kimikazu, and Nakasone, Hideki

Published
2022
Full Text
View/download PDF

24. Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group

Author

Fuji, Shigeo, Hirakawa, Tsuneaki, Takano, Kuniko, Doki, Noriko, Sawa, Masashi, Kanda, Yoshinobu, Uchida, Naoyuki, Ara, Takahide, Miyamoto, Toshihiro, Eto, Tetsuya, Matsuoka, Ken-ichi, Kawakita, Toshiro, Ozawa, Yukiyasu, Katayama, Yuta, Onizuka, Makoto, Fukuda, Takahiro, Atsuta, Yoshiko, and Nakasone, Hideki

Published
2022
Full Text
View/download PDF

26. Improved Long-Term Net Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies over Two Decades

Author

Ohbiki, Marie, Ito, Yuri, Inamoto, Yoshihiro, Miyamura, Koichi, Uchida, Naoyuki, Fukuda, Takahiro, Fujiwara, Hiroki, Nishida, Tetsuya, Hayashi, Masayasu, Tanaka, Masatsugu, Kawakita, Toshiro, Ikegame, Kazuhiro, Katayama, Yuta, Ara, Takahide, Ichinohe, Tatsuo, Kiyoi, Hitoshi, Matsuo, Keitaro, and Atsuta, Yoshiko

Published
2023
Full Text
View/download PDF

31. Prognostic impact of complex and/or monosomal karyotypes in post‐transplant poor cytogenetic acute myeloid leukaemia: Aquantitative approach

Author

Jo, Tomoyasu, Arai, Yasuyuki, Oshima, Shinichiro, Kondo, Tadakazu, Harada, Kaito, Uchida, Naoyuki, Doki, Noriko, Fukuda, Takahiro, Tanaka, Masatsugu, Ozawa, Yukiyasu, Kuriyama, Takuro, Ikegame, Kazuhiro, Katayama, Yuta, Ota, Shuichi, Ara, Takahide, Kawakita, Toshiro, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yanada, Masamitsu

Subjects
complex karyotype, allogeneic stem cell transplantation, acute myeloid leukaemia, monosomal karyotype
Abstract

To evaluate the prognostic impact of complex karyotype (CK) and/or monosomal karyotype (MK) in combination with various clinical factors on allogeneic stem cell transplantation (HSCT) outcomes of patients with acute myeloid leukaemia (AML), we analysed the registry database of adult AML patients who underwent allogeneic HSCT between 2000 and 2019 in Japan. Among 16 094 patients, those with poor cytogenetic risk (N = 3345) showed poor overall survival (OS) after HSCT (25.3% at 5 years). Multivariate analyses revealed that CK and/or MK (hazard ratio [HR], 1.31 for CK without MK; 1.27 for MK without CK; and 1.73 for both), age at HSCT ≥50 years (HR, 1.58), male sex (HR, 1.40), performance status ≥2 (HR, 1.89), HCT-CI score ≥3 (HR, 1.23), non-remission status at HSCT (HR, 2.49), and time from diagnosis to HSCT ≥3 months (HR, 1.24) independently reduced post-HSCT OS among patients with poor cytogenetic risk AML. A risk scoring system based on the multivariate analysis successfully stratified patients into five distinct groups for OS. This study confirms the negative effects of CK and MK on post-HSCT outcomes, and offers a powerful risk scoring system for predicting prognoses after HSCT among AML patients with unfavourable cytogenetics.

Published
2023

32. Ideal Body Weight Is Useful For Predicting Neutrophil Engraftment and Platelet Recovery for Overweight and Obese Recipients in Single-Unit Cord Blood Transplantation

Author

Okada, Yosuke, Nakasone, Hideki, Konuma, Takaaki, Uchida, Naoyuki, Tanaka, Masatsugu, Sugio, Yasuhiro, Aotsuka, Nobuyuki, Nishijima, Akihiko, Katsuoka, Yuna, Ara, Takahide, Ota, Shuichi, Onizuka, Makoto, Sawa, Masashi, Kimura, Takafumi, Fukuda, Takahiro, Atsuta, Yoshiko, Kanda, Junya, and Kimura, Fumihiko

Published
2022
Full Text
View/download PDF

34. Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group

Author

Kimura, Shun-ichi, Kameda, Kazuaki, Harada, Kaito, Saburi, Masuho, Okinaka, Keiji, Shinohara, Akihito, Uchida, Naoyuki, Nishijima, Akihiko, Ozawa, Yukiyasu, Tanaka, Masatsugu, Kuriyama, Takuro, Katayama, Yuta, Sawa, Masashi, Ikegame, Kazuhiro, Kawakita, Toshiro, Kanda, Yoshinobu, Nakamae, Hirohisa, Ara, Takahide, Kimura, Takafumi, Sato, Atsushi, Fukuda, Takahiro, Atsuta, Yoshiko, and Nakasone, Hideki

Published
2022
Full Text
View/download PDF

35. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation

Author

Miyao, Kotaro, Kuwatsuka, Yachiyo, Murata, Makoto, Nagafuji, Koji, Teshima, Takanori, Takeuchi, Yuki, Shiratori, Souichi, Najima, Yuho, Uchida, Naoyuki, Tanaka, Masatsugu, Sawa, Masashi, Ota, Shuichi, Fukuda, Takahiro, Ozawa, Yukiyasu, Kako, Shinichi, Kawakita, Toshiro, Ara, Takahide, Tanaka, Junji, Kanda, Yoshinobu, Atsuta, Yoshiko, Kanda, Junya, and Terakura, Seitaro

Published
2022
Full Text
View/download PDF

36. Comparison of fludarabine‐based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry‐based study.

Author

Kurita, Naoki, Imahashi, Nobuhiko, Chiba, Shigeru, Tanaka, Masatsugu, Kobayashi, Hikaru, Uchida, Naoyuki, Kuriyama, Takuro, Anzai, Naoyuki, Nawa, Yuichiro, Nakano, Nobuaki, Ara, Takahide, Onizuka, Makoto, Katsuoka, Yuna, Koi, Satoshi, Kimura, Takafumi, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Kanda, Junya

Published
2024
Full Text
View/download PDF

37. Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy.

Author

Watanabe, Mizuki, Kanda, Junya, Fukuda, Takahiro, Uchida, Naoyuki, Ikegame, Kazuhiro, Kataoka, Keisuke, Kobayashi, Hikaru, Ara, Takahide, Ishikawa, Jun, Matsuoka, Ken‐ichi, Sugio, Yasuhiro, Nakazawa, Hideyuki, Ikeda, Takashi, Atsuta, Yoshiko, Kondo, Eisei, and Suzuki, Ritsuro

Subjects
CELLULAR therapy, LYMPHOMAS, JAPANESE people, PROGRESSION-free survival, STEM cell transplantation
Abstract

Summary: The graft‐versus‐lymphoma (GVL) effect and its association with acute and chronic GVHD (aGVHD, cGVHD) has not been comprehensively elucidated. We retrospectively analysed 2204 Japanese patients with non‐Hodgkin lymphomas (NHLs; indolent B‐NHLs, n = 689; aggressive B‐NHLs, n = 720; mature T/NK‐NHLs, n = 795) receiving a first allo‐HSCT in 2003–2017. Pre‐transplant lymphoma control showed complete response (CR) in 759 and non‐CR in 1445. We assessed the impact of aGVHD/cGVHD on lymphoma progression and other outcomes. Although aGVHD/cGVHD showed no statistical impact on lymphoma progression in the overall cohort, their impact was clear in certain groups: Grade I‐II aGVHD in CR patients (HR, 0.63; 95% CI, 0.43–0.91), especially in mature T/NK‐NHL (HR, 0.46; 95% CI, 0.26–0.83) and extensive cGVHD in patients with mature aggressive B‐NHLs (HR, 0.55; 95% CI, 0.31–0.97). In total, limited cGVHD was associated with superior survivals (progression‐free survival: HR, 0.71; 95% CI, 0.56–0.90), whereas severe GVHDs showed negative impacts on them. Our results support the presence of GVL effects differentially associated with GVHD in different lymphoma subtypes/controls. Meanwhile, it was also suggested that we should manage GVHDs within a limited activity, considering the negative impact of severe GVHDs. As pre‐transplant lymphoma control remains a strong factor influencing transplant outcomes, improving its management is an important issue to be addressed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group.

Author

Yanagisawa, Ryu, Tamaki, Masaharu, Tanoshima, Reo, Misaki, Yukiko, Uchida, Naoyuki, Koi, Satoshi, Tanaka, Takashi, Ozawa, Yukiyasu, Matsuo, Yayoi, Tanaka, Masatsugu, Ikegame, Kazuhiro, Katayama, Yuta, Matsuoka, Ken‐ichi, Ara, Takahide, Kanda, Yoshinobu, Matsumoto, Kimikazu, Fukuda, Takahiro, Atsuta, Yoshiko, Kato, Motohiro, and Nakasone, Hideki

Subjects
CELLULAR therapy, DISEASE risk factors, HEMATOPOIETIC stem cell transplantation, THERAPEUTIC complications, CARDIOVASCULAR disease related mortality, STEM cell transplantation, MEDICAL records
Abstract

Fatal cardiac complications can occur from the early to late phases after hematopoietic cell transplantation (HCT). Herein, the Japanese transplant registry database was used to retrospectively analyze health records of 33,791 allogeneic HCT recipients to elucidate the pathogenesis and risk factors involved. Overall, 527 patients died of cardiac complications at a median of 130 (range 0–3924) days after HCT. The cumulative incidence of fatal cardiac complications was 1.2% (95% confidence interval [CI]: 1.0–1.3) and 1.6% (95% CI: 1.5–1.8) at 1 and 5 years after HCT, respectively. Fatal cardiovascular events were significantly associated with an HCT‐specific comorbidity index (HCT‐CI) score of ≥1 specific to the three cardiovascular items, lower performance status, conditioning regimen cyclophosphamide dose of >120 mg/kg, and female sex. Cardiovascular death risk within 60 days after HCT was associated with the type of conditioning regimen, presence of bacterial or fungal infections at HCT, and number of blood transfusions. Contrastingly, late cardiovascular death beyond 1 year after HCT was associated with female sex and older age. Lower performance status and positive cardiovascular disease‐related HCT‐CI were risk factors for cardiac complications in all phases after HCT. Systematic follow‐up may be necessary according to the patients' risk factors and conditions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era.

Author

Ishida, Hisashi, Shimada, Hiroyuki, Tanizawa, Akihiko, Shimazu, Yutaka, Tachibana, Takayoshi, Doki, Noriko, Ara, Takahide, Matsuo, Yayoi, Nara, Miho, Toubai, Tomomi, Ino, Kazuko, Nakamae, Hirohisa, Kato, Keisuke, Kato, Koji, Sato, Atsushi, Hino, Moeko, Matsumoto, Kimikazu, Atsuta, Yoshiko, Yasui, Masahiro, and Nagamura‐Inoue, Tokiko

Published
2023
Full Text
View/download PDF

40. Intestinal Lymphatic Endothelial Cells Produce R-Spondin3

Author

Ogasawara, Reiki, Hashimoto, Daigo, Kimura, Shunsuke, Hayase, Eiko, Ara, Takahide, Takahashi, Shuichiro, Ohigashi, Hiroyuki, Yoshioka, Kosuke, Tateno, Takahiro, Yokoyama, Emi, Ebata, Ko, Kondo, Takeshi, Sugita, Junichi, Onozawa, Masahiro, Iwanaga, Toshihiko, and Teshima, Takanori

Published
2018
Full Text
View/download PDF

41. Donor Selection Considering Donor Age in Hematopoietic Cell Transplant Recipients 50-75 Years of Age

Author

Seo, Sachiko, Kanda, Junya, Kono, Kenta, Inamoto, Yoshihiro, Uchida, Naoyuki, Doki, Noriko, Tanaka, Masatsugu, Sawa, Masashi, Onizuka, Makoto, Katayama, Yuta, Eto, Tetsuya, Matsuoka, Ken-ichi, Fukuda, Takahiro, Ara, Takahide, Ozawa, Yukiyasu, Kawakita, Toshiro, Kato, Keisuke, Uchiyama, Koji, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Kimura, Fumihiko

Published
2022
Full Text
View/download PDF

42. Prognostic impact of complex and/or monosomal karyotypes in post‐transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach.

Author

Jo, Tomoyasu, Arai, Yasuyuki, Oshima, Shinichiro, Kondo, Tadakazu, Harada, Kaito, Uchida, Naoyuki, Doki, Noriko, Fukuda, Takahiro, Tanaka, Masatsugu, Ozawa, Yukiyasu, Kuriyama, Takuro, Ikegame, Kazuhiro, Katayama, Yuta, Ota, Shuichi, Ara, Takahide, Kawakita, Toshiro, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yanada, Masamitsu

Subjects
ACUTE myeloid leukemia, STEM cell transplantation, KARYOTYPES, STEM cell factor, DISEASE risk factors, HEMATOPOIETIC stem cell transplantation
Abstract

Summary: To evaluate the prognostic impact of complex karyotype (CK) and/or monosomal karyotype (MK) in combination with various clinical factors on allogeneic stem cell transplantation (HSCT) outcomes of patients with acute myeloid leukaemia (AML), we analysed the registry database of adult AML patients who underwent allogeneic HSCT between 2000 and 2019 in Japan. Among 16 094 patients, those with poor cytogenetic risk (N = 3345) showed poor overall survival (OS) after HSCT (25.3% at 5 years). Multivariate analyses revealed that CK and/or MK (hazard ratio [HR], 1.31 for CK without MK; 1.27 for MK without CK; and 1.73 for both), age at HSCT ≥50 years (HR, 1.58), male sex (HR, 1.40), performance status ≥2 (HR, 1.89), HCT‐CI score ≥3 (HR, 1.23), non‐remission status at HSCT (HR, 2.49), and time from diagnosis to HSCT ≥3 months (HR, 1.24) independently reduced post‐HSCT OS among patients with poor cytogenetic risk AML. A risk scoring system based on the multivariate analysis successfully stratified patients into five distinct groups for OS. This study confirms the negative effects of CK and MK on post‐HSCT outcomes, and offers a powerful risk scoring system for predicting prognoses after HSCT among AML patients with unfavourable cytogenetics. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan.

Author

Konuma, Takaaki, Itonaga, Hidehiro, Ishiyama, Ken, Hamamura, Atsushi, Uchida, Naoyuki, Ozawa, Yukiyasu, Katayama, Yuta, Sakurai, Masatoshi, Ueda, Yasunori, Matsuoka, Ken‐ichi, Kawakita, Toshiro, Eto, Tetsuya, Ara, Takahide, Kanda, Junya, Onizuka, Makoto, Fukuda, Takahiro, and Atsuta, Yoshiko

Published
2023
Full Text
View/download PDF

44. Intensified conditioning regimens improved disease‐free survival and engraftment after unrelated single‐unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation.

Author

Konuma, Takaaki, Kanda, Junya, Uchida, Naoyuki, Nishijima, Akihiko, Tanaka, Masatsugu, Ozawa, Yukiyasu, Sawa, Masashi, Onizuka, Makoto, Ota, Shuichi, Maruyama, Yumiko, Kanda, Yoshinobu, Kawakita, Toshiro, Ara, Takahide, Eto, Tetsuya, Nakamae, Hirohisa, Kimura, Takafumi, Fukuda, Takahiro, and Atsuta, Yoshiko

Subjects
CORD blood transplantation, HEMATOPOIETIC stem cell transplantation, PROGRESSION-free survival, TOTAL body irradiation, GRAFT versus host disease, RADIATION injuries
Abstract

The impact of conditioning intensity on different donor groups has been unclear in allogeneic transplantation. The objective of this study was to clarify the effect of conditioning intensity on disease‐free survival (DFS), relapse, non‐relapse mortality (NRM), neutrophil engraftment, and graft‐versus‐host disease for each donor type. We retrospectively evaluated the effect of conditioning intensity on transplant outcomes for patients with acute leukemia or myelodysplastic syndrome aged between 16 and 60 years in Japan using the transplant conditioning intensity (TCI) scoring system. A total of 8526 patients who received first allogeneic transplantation from 6/6 antigen‐matched sibling donor (MSD, n = 2768), 8/8 allele‐matched unrelated donor (MUD, n = 2357), and unrelated single‐cord blood (UCB, n = 3401) were eligible for the analyses. Compared to conditioning with TCI score 4.0, which was corresponds to conventional myeloablative conditioning, including cyclophosphamide with total body irradiation 12 Gy or busulfan 12.8 mg, and was considered as the reference group in the multivariate analyses, intensified conditioning with TCI score ≥4.5 improved DFS (hazard ratio [HR],0.81, P < 0.001) and relapse rate (HR, 0.70, P < 0.001) but only after UCB transplants and not MSD and MUD transplants. In contrast, NRM was higher after intensified conditioning with TCI score ≥4.5 for MSD (HR, 1.39, P = 0.008) and MUD (HR, 1.47, P = 0.002) transplants but not UCB transplants (HR, 1.12, P = 0.240). Neutrophil engraftment was also significantly higher after intensified conditioning with TCI score ≥4.5 but only for UCB transplants (HR, 1.24, P < 0.001), whereas it was significantly lower after reduced‐intensity conditioning with TCI score ≤3.5 for MSD transplants only (HR, 0.82, P < 0.001). These data demonstrated that an intensified conditioning regimen improved survival and engraftment rate only after a UCB transplants. Therefore, TCI scoring system could enable the optimization of conditioning intensity according to donor type, particularly in terms of survival and engraftment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. P1261: NEGATIVE IMPACT OF HLA‐B LEADER MISMATCH ON OUTCOMES OF HCT WITH PTCY FOR LYMPHOID MALIGNANCIES: A RETROSPECTIVE ANALYSIS FROM THE JAPANESE SOCIETY FOR TRANSPLANTATION AND CELLULAR THERAPY.

Author

Kanaya, Minoru, Hashimoto, Daigo, Nakamae, Hirohisa, Ara, Takahide, Fukuda, Takahiro, Nagafuji, Koji, Eto, Tetsuya, Hiramoto, Nobuhiro, Maruyama, Yumiko, Ota, Shuichi, Matsuoka, Ken‐Ichi, Akasaka, Takashi, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Morishima, Satoko

Published
2023
Full Text
View/download PDF

46. Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI.

Author

Morita‐Fujita, Mari, Arai, Yasuyuki, Kondo, Tadakazu, Harada, Kaito, Uchida, Naoyuki, Toya, Takashi, Ozawa, Yukiyasu, Fukuda, Takahiro, Ota, Shuichi, Onizuka, Makoto, Kanda, Yoshinobu, Maruyama, Yumiko, Takada, Satoru, Kawakita, Toshiro, Ara, Takahide, Ichinohe, Tatsuo, Kimura, Takafumi, Atsuta, Yoshiko, and Kako, Shinichi

Subjects
HEMATOPOIETIC stem cell transplantation, ADULTS, LYMPHOBLASTIC leukemia
Abstract

The medium‐dose etoposide (VP16) added on cyclophosphamide (CY)/total body irradiation (TBI) is one of the intensified myeloablative conditioning regimens used in allogenic hematopoietic stem cell transplantation (allo‐HSCT) for acute lymphoblastic leukemia (ALL). However, the patient subgroups who can actually benefit from VP16/CY/TBI compared to CY/TBI have not been precisely defined. Therefore, we conducted a multi‐center retrospective study using the Japanese nationwide registry database to elucidate the efficacy of VP16/CY/TBI on post‐transplant prognosis. Biological and clinical distinct subtypes (i.e., Philadelphia chromosome‐positive (Ph+) and ‐negative (Ph−) ALL) were evaluated separately, which included 820 Ph+ and 1463 patients with Ph− ALL, respectively. Compared with the CY/TBI group, the VP16/CY/TBI group showed superior progression‐free survival (PFS) in patients with Ph+ ALL (65% vs. 57% at 3 years after HSCT; adjusted hazard ratio (HR), 0.73; 95% confidence interval (CI), 0.55–0.98; p = 0.03), along with significantly reduced incidence of relapse (adjusted HR, 0.58; 95% CI, 0.37–0.90; p = 0.02) without the increase of non‐relapse mortality (NRM). By contrast, in patients with Ph− ALL, VP16/CY/TBI did not improve PFS nor incidence of relapse; addition of VP16 reduced relapse (HR, 0.65; p = 0.06) in patients with Ph− ALL transplanted at CR1, while improved PFS was not observed (HR, 0.90; p = 0.52) due to increased NRM. This study demonstrated that VP16/CY/TBI is a more effective and well‐tolerated regimen in comparison with CY/TBI in patients with myeloablative allo‐HSCT for adult Ph+ ALL. Our findings can provide a novel algorithm for conditioning regimen selection in patients with adult ALL. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Haploidentical transplantation with post‐transplant cyclophosphamide versus single cord blood transplantation for myelodysplastic syndrome: A retrospective study from the Adult Myelodysplastic Syndrome Working Group of the Japanese Society for Transplantation and Cellular Therapy (JSTCT)

Author

Konuma, Takaaki, Shimomura, Yoshimitsu, Ishiyama, Ken, Ara, Takahide, Nakamae, Hirohisa, Hiramoto, Nobuhiro, Eto, Tetsuya, Maruyama, Yumiko, Nagafuji, Koji, Ishikawa, Jun, Uchida, Naoyuki, Tanaka, Masatsugu, Onizuka, Makoto, Ueda, Yasunori, Anzai, Naoyuki, Kimura, Takafumi, Kanda, Yoshinobu, Fukuda, Takahiro, and Atsuta, Yoshiko

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results